On 6 June 2017, the World Health Organization (WHO) published updates to its ‘Essential Medicines List’ (EML). Read more here.

Extended deadline (from 1 July to 31 July) 2017 for call to submit papers on effectiveness and cost-effectiveness of screening and prevention of infectious diseases among newly arrived migrants in Europe. Read more here.

Eurosurveillance is on the updated list of the Directory of Open Access Journals and in the SHERPA/RoMEO database. Read more here.

Follow Eurosurveillance on Twitter: @Eurosurveillanc

In this issue

Home Eurosurveillance Edition  2015: Volume 20/ Issue 49 Article 3
Back to Table of Contents
Previous Download (pdf)

Eurosurveillance, Volume 20, Issue 49, 10 December 2015
Rapid communication
Chu, Oladipo, Perera, Kuranga, Chan, Poon, and Peiris: Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015

+ Author affiliations

Citation style for this article: Chu DK, Oladipo JO, Perera RA, Kuranga SA, Chan SM, Poon LL, Peiris M. Middle East respiratory syndrome coronavirus (MERS-CoV) in dromedary camels in Nigeria, 2015. Euro Surveill. 2015;20(49):pii=30086. DOI:

Received:10 November 2015; Accepted:10 December 2015


Middle East respiratory syndrome coronavirus (MERS-CoV) is a novel lineage C betacoronavirus that can cause an acute viral respiratory disease in humans. As of 13 November 2015, there were 1,618 laboratory-confirmed cases of MERS reported to the World Health Organization (WHO), associated with 579 deaths [1,2]. Human disease is zoonotic in origin, although clusters of human-to-human transmission have been reported, especially within healthcare or family settings [1]. Dromedary camels in the Middle East have a high seroprevalence for MERS-CoV and MERS-CoV RNA has been consistently detected in these animals, especially in settings such as camel abattoirs, where camels from multiple origins are assembled. Camels are thus identified as a potential source of zoonotic MERS [3-6]. More than 60% of the global population of dromedary camels is distributed in African countries. Some of these countries are important camel exporters to the Arabian Peninsula [7]. MERS-CoV antibodies were also found with high prevalence in dromedary camels in these African countries with positive rates higher than 80% for the animals in Egypt, Ethiopia, Nigeria and Sudan, and of 30 to 54% in Tunisia [8]. However, zoonotic human disease has so far been reported only from countries in the Middle-East. The reason for the absence of zoonotic disease in Africa is unclear.

The genetic diversity of the virus in Africa is poorly defined. The only reports of genetic sequences from Africa have been those from viruses in Egypt and these were genetically distinct from those currently causing human disease in the Middle East [6]. However, phenotypic characterisation of these viruses revealed they have capacity to infect tissues of the human respiratory tract [9]. There is a need to better understand the ecology of MERS-CoV within Africa and the viral genetic diversity within this region. We report detection rates of MERS-CoV in dromedary camels in the abattoir in Kano, Nigeria, where around 55 camels are slaughtered per day, making it the largest camel abattoir in that country. Viral sequences derived from nasal swabs of these animals are also phylogenetically analysed.


The study was carried out on seven consecutive days in January 2015. Nasal swabs and blood were collected from camels shortly after slaughter at the abattoir in Kano, Nigeria. Some of the animals slaughtered at this abattoir originate from northern Nigeria, as well as neighbouring African countries including Chad, Libya, Mali, Niger and Sudan. Nasal swabs were collected in RNALater (Ambion) or in virus transport medium and stored at -80 °C. Blood samples were collected and serum separated. The age of the sampled camels was assessed by dental examination. Samples were shipped to the laboratory at The University of Hong Kong on dry ice for laboratory investigation.

Total nucleic acid was extracted from swab samples using EasyMag (Biomerieux), and tested for the presence of MERS-CoV RNA by upstream of the Envelope gene (UpE) reverse transcription-quantitative polymerase chain reaction (RT-qPCR) hydrolysis probe assay. All positive specimens were confirmed by a second RT-qPCR assay targeting the open reading frame (ORF)1a region of the genome [6]. The S2 region of the positive samples were amplified and sequenced for phylogenetic characterisation [10]. The full spike gene and 5kb of the ORF1b region of one virus were sequenced for more detailed analysis.

Sera were screened at a dilution of 1:20 for the detection of MERS-CoV antibody using a validated MERS-spike pseudoparticle neutralisation test (ppNT) as previously described [5].


Overall, 132 of the 385 animals slaughtered during this period (34%; daily range: 24%–43%) were sampled shortly after slaughter. Nasal swabs were collected from all 132 camels, while serum samples were obtained from 131.

MERS-CoV RNA was detected by both UpE and ORF-1a RT-qPCR assays in 14 (11%), nasal swabs with positive samples being found in five of the seven days sampled (Table). Threshold cycles of the positives by UpE assay ranged from 23.8 to 37.4, which represented 3.54x102 to 2.60x106 copies of virus RNA per 1 mL of original swab sample. Ages of the MERS-CoV positive animals ranged from three to 12 years-old.


Swabs and sera collected from dromedary camels and results of reverse transcription-quantitative polymerase chain reaction and serology for Middle East respiratory syndrome coronavirus, Nigeria, January 2015

Sampling date Number of camels slaughtered Swabs sampled Swabs positive n (%) Sera sampled Sera positive
n (%)
13 Jan 2015 45 11 4 (36) 11 9 (82)
14 Jan 2015 54 17 6 (35) 17 16 (94)
15 Jan 2015 50 18 0 (0) 18 18 (100)
16 Jan 2015 48 15 1 (7) 15 15 (100)
17 Jan 2015 70 30 2 (7) 30 28 (93)
18 Jan 2015 55 19 1 (5) 19 19 (100)
19 Jan 2015 63 22 0 (0) 21 20 (95)
Total 385 132 14 (11) 131 125 (95)

On a daily basis, the seroprevalence ranged from 82% to 100%, giving an overall seroprevalence of 95% (Table). All 14 animals positive by RT-qPCR were also positive for MERS-CoV antibody by ppNT. The highest MERS-CoV RNA positive rate by RT-qPCR was detected on the days with lowest seroprevalence.

We sequenced a 600 bp region in S2 gene of six selected RT-qPCR positive samples, representing at least one positive sample from each day with PCR-positive samples. Phylogenetic analysis showed that these six viruses formed two distinct lineages, the virus from a camel sampled on 16 January being distinct from the others (Figure 1).

Figure 1

Phylogenetic analysis of the Middle East respiratory syndrome coronaviruses (MERS-CoVs) recovered from Nigeria


Phylogenetic tree of S2 (600 bp) gene sequences obtained by neighbour-joining method with bootstrap values >60 indicated. The tree is mid-point rooted. Sequences generated from this study are in bold with GenBank accession numbers: KU201953–58. Accession numbers of other sequences retrieved from GenBank are shown in brackets.

Both of the Nigerian virus groups were distinct from previously known virus lineages. The Nigerian camel viruses were most closely related to virus NRCE-HKU270 previously found in Egypt with nt sequence similarity of 99.3 to 99.6%. MERS-CoV in Nigeria were genetically distinct from viruses found in camels in the Middle East and viruses detected in humans in more recent years (nt sequence similarity ranging from 98.4 to 99.4%) (Figure 2).

Figure 2

Pairwise similarities between nucleotide sequences of spike S2 region of Middle East respiratory syndrome coronaviruses, including several recovered from Nigeria and other representative viruses


ID: identical virus.

The time-resolved phylogeny of the ORF1b region of one virus confirms these overall findings (Figure 3).

Figure 3

Time resolved phylogenetic tree of open reading frame (ORF)1b of Middle East respiratory syndrome coronaviruses (MERS-CoVs) recovered in Africa and the Middle East, 2012–2015


The time resolved phylogenetic tree was constructed using Bayesian evolutionary analysis by sampling trees (BEAST) with an uncorrelated lognormal relaxed clock based on open reading frame (ORF)1b (5,347 bp) gene sequences of representative MERS-CoVs. Median ages of the nodes with respective to MERS-CoV ChinaGD (the latest virus included) are shown. The tree is rooted to bat coronavirus Neoromicia. The sequence generated from this study (Nigeria-HKU004) is in bold and has GenBank accession number KU201959. GenBank accession numbers of other sequences retrieved for the phylogenetic analysis are shown in brackets.

We derived the nt sequence of the full spike gene of one virus Nigeria HKU004 and the deduced amino acid sequence is aligned and compared to those of other human and animal MERS-CoV in Figure 4. This reveals that the receptor binding domain, which is crucial for virus host range and tropism, is fully conserved. There are only two amino acid residues not previously reported in other MERS-CoV spike proteins; these being S 656 T and L 1200 F.

Figure 4

Alignment of the full spike protein amino acid sequence of a Middle East respiratory syndrome coronavirus (MERS-CoV) found in Nigeria with those of other MERS-CoVs


GenBank accession number for MERS-CoV Nigeria HKU004 was KU201953.

RBD: receptor binding domain; UD: undefined.


We report high MERS-CoV seroprevalence in camels gathered in an abattoir in Nigeria with relatively high detection rates of virus in nasal swabs. Phylogenetic analysis revealed that these viruses are genetically distinct from viruses reported from camels or humans in the Arabia peninsula and cluster with, but are clearly distinct from those reported from Egypt. However, it is important to note that these Nigerian viruses remain genetically closely related to other MERS-CoV with an overall nt similarity of > 0.98 for the S2 gene. Thus these are almost certainly pertaining to one viral species, and very likely (though not directly studied in the present work) also form one serotype.

Although the animals in this study were sampled in Kano, Nigeria, some animals originated from neighbouring African countries. The camels are kept within the abattoir for a number of days before slaughter allowing opportunity for virus cross-infection and amplification. Thus the viruses detected in this study may reflect viruses circulating in this wider region.

A limitation of this study is the short period within which the sampling was carried out. Thus it is unclear whether the high rate of virus detection reflects an all year-round pattern or if there are seasonal differences in virus activity. It has been suspected that virus activity in camels may increase during the calving season. In Nigeria, as in the Arabian peninsula, camel calving peaks during the January to March period. Thus it is possible that the rate of virus detection observed in this study reflects a seasonal peak. Indeed this was the rationale for targeting sampling within this time frame. Even if the observations of this study reflect a seasonal peak, the detection of MERS-CoV in camels slaughtered on five of seven days sampled, suggests intense exposure of humans to virus infected camels, whether seasonally or year round, and thus potentially a significant zoonotic threat.

It is not known if the MERS-CoV in Nigeria has similar zoonotic potential to viruses currently circulating in the Arabian peninsula. Other explanations for the lack of zoonotic MERS in Africa include differences in patterns of exposure to infected animals or animal products or differences in human susceptibility to MERS-CoV. Alternatively, MERS may indeed be occurring but unrecognised in Africa due to lack of awareness or diagnostic testing.

A second limitation of this study is that there were no virus isolates available for phenotypic characterisation and full genome sequence data were not available for genetic comparison across the whole genome with viruses known to infect humans. Comparison of the sequence of the spike gene with other MERS-CoV suggests that the virus isolated in Nigeria appears to have competence to bind the dipeptidyl peptidase (DPP)-4 receptor. Viruses isolated from Egypt, though genetically distinct, had comparable tropism and replication competence in ex vivo cultures of the human bronchus and lung to those viruses isolated from humans in Saudi Arabia [9]. Thus zoonotic potential of these viruses cannot be excluded. Further studies to determine the genetic diversity and biological characterisation of MERS-CoV across Africa are urgently needed. Studies looking into seroprevalence of humans exposed to settings associated with such high levels of exposure to MERS-CoV such as camel abattoirs across Africa are also important to assess the extent of zoonotic spill-over, if any.


This study is supported by a research grant from the US National Institutes of Health (contract No. HHSN272201400006C).

Conflict of interest

None declared.

Authors’ contributions

JOO and MP designed the study, JOO and SAK carried out the field work, DKWC, RAPMP, SMSC and LLMP supervised and carried out the laboratory analysis, DKWC and MP drafted the manuscript. All authors critically reviewed the manuscript.


  1. World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV): Summary of Current Situation, Literature Update and Risk Assessment. 7 July 2015. [Accessed 23 Oct 2015]. Available from:

  2. World Health Organization (WHO). Middle East respiratory syndrome coronavirus (MERS-CoV) – Saudi Arabia. Disease outbreak news. 13 November 2015. Available from:

  3. Haagmans BL, Al Dhahiry SHS, Reusken CBEM, Raj VS, Galiano M, Myers R,  et al.  Middle East respiratory syndrome coronavirus in dromedary camels: an outbreak investigation. Lancet Infect Dis. 2014;14(2):140-5. DOI: 10.1016/S1473-3099(13)70690-X PMID: 24355866

  4. Reusken CB, Haagmans BL, Müller MA, Gutierrez C, Godeke GJ, Meyer B,  et al.  Middle East respiratory syndrome coronavirus neutralising serum antibodies in dromedary camels: a comparative serological study. Lancet Infect Dis. 2013;13(10):859-66. DOI: 10.1016/S1473-3099(13)70164-6 PMID: 23933067

  5. Perera RA, Wang P, Gomaa MR, El-Shesheny R, Kandeil A, Bagato O,  et al.  Seroepidemiology for MERS coronavirus using microneutralisation and pseudoparticle virus neutralisation assays reveal a high prevalence of antibody in dromedary camels in Egypt, June 2013. Euro Surveill. 2013;18(36):20574. DOI: 10.2807/1560-7917.ES2013.18.36.20574 PMID: 24079378

  6. Chu DKW, Poon LLM, Gomaa MM, Shehata MM, Perera RAPM, Abu Zeid D,  et al.  MERS coronaviruses in dromedary camels, Egypt. Emerg Infect Dis. 2014;20(6):1049-53. DOI: 10.3201/eid2006.140299 PMID: 24856660

  7. Faye B, Bonnet P. Camel sciences and economy in the world: Current situation and perspectives. In: Johnson EH, Mascarina CS, Eds. Proceedings of Emerging Diseases of Camelids, 3rd Conference on the International Society of Camelid Research and Development; 29 January–1 February 2012, Muscat, Oman. p 2-15.

  8. Reusken CB, Messadi L, Feyisa A, Ularamu H, Godeke GJ, Danmarwa A,  et al.  Geographic distribution of MERS coronavirus among dromedary camels, Africa. Emerg Infect Dis. 2014;20(8):1370-4. DOI: 10.3201/eid2008.140590 PMID: 25062254

  9. Chan RW, Hemida MG, Kayali G, Chu DK, Poon LL, Alnaeem A,  et al.  Tropism and replication of Middle East respiratory syndrome coronavirus from dromedary camels in the human respiratory tract: an in-vitro and ex-vivo study. Lancet Respir Med. 2014;2(10):813-22. DOI: 10.1016/S2213-2600(14)70158-4 PMID: 25174549

  10. Smits SL, Raj VS, Pas SD, Reusken CB, Mohran K, Farag EA,  et al.  Reliable typing of MERS-CoV variants with a small genome fragment. J Clin Virol. 2015;64:83-7. DOI: 10.1016/j.jcv.2014.12.006 PMID: 25728084

Back to Table of Contents
Previous Download (pdf)

The publisher’s policy on data collection and use of cookies.

Disclaimer: The opinions expressed by authors contributing to Eurosurveillance do not necessarily reflect the opinions of the European Centre for Disease Prevention and Control (ECDC) or the editorial team or the institutions with which the authors are affiliated. Neither ECDC nor any person acting on behalf of ECDC is responsible for the use that might be made of the information in this journal. The information provided on the Eurosurveillance site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician. Our website does not host any form of commercial advertisement. Except where otherwise stated, all manuscripts published after 1 January 2016 will be published under the Creative Commons Attribution (CC BY) licence. You are free to share and adapt the material, but you must give appropriate credit, provide a link to the licence, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

Eurosurveillance [ISSN] - ©2007-2016. All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.